EU-101 is under clinical development by Eutilex and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EU-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EU-101 is under development for the treatment of solid tumors including non-small cell lung cancer and colorectal cancer. The therapeutic candidate is a monoclonal antibody developed based on the immunomodulatory platform technology. It is administered by intravenous route and acts by targeting 4-1BB also called CD137.
Eutilex Co. Ltd., a clinical-stage biopharmaceutical company that develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. The company is headquartered in Republic of Korea (South Korea).
For a complete picture of EU-101’s drug-specific PTSR and LoA scores, buy the report here.